ConductScience.org, home

Library / Trial comparisons

Flublok Recipients vs SD-IIV Recipients: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNoteSource
Risk in group 10.0005560.0005010.000617wilsonClinicalTrials.gov
Risk in group 20.0005020.000460.000548wilsonClinicalTrials.gov
Risk difference, group 1 minus group 20.0000538-0.0000180.000128newcombe hybrid scoreClinicalTrials.gov
Risk ratio, group 1 over group 21.110.9661.27logClinicalTrials.gov
Odds ratio, group 1 over group 21.110.9661.27logClinicalTrials.gov
Number needed to harm, for one more death from any cause on Flublok Recipients than on SD-IIV Recipients18,600from the risk difference intervalthe interval includes no differenceClinicalTrials.gov

Groups 2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov codeSource
Group 1Flublok Recipients
Kaiser Permanente Northern California members aged 18-64 years who receive Flublok Quadrivalent vaccine.~Flublok Quadrivalent: Flublok Quadrivalent vaccine is a recombinant hemagglutinin influenza vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine for adults 18 years of age and older. Use of recombinant DNA techniques to produce vaccine antigen expressed in cell culture is a method that avoids growing the influenza viruses in embryonated hen's eggs.
352632,962EG000ClinicalTrials.gov
Group 2SD-IIV Recipients
Kaiser Permanente Northern California members aged 18-64 years who receive standard dose inactivated influenza vaccine (SD-IIV).~Standard Dose Inactivated Influenza Vaccine (SD-IIV): For the 2018-2019, 2019-2020, and 2020-2021 flu seasons, the primary SD-IIVs used will be Fluarix Quadrivalent and Flulaval Quadrivalent.
501997,366EG001ClinicalTrials.gov

Harm 2

FieldValueSource
What it countsTotal, all-cause mortalityClinicalTrials.gov
Time frameClinicalTrials.gov

Trial 8

FieldValueSource
TitleFlublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 YearsClinicalTrials.gov
NCT numberNCT03694392ClinicalTrials.gov
PhasesClinicalTrials.gov
ConditionsInfluenza, Pneumonia, Lower Respiratory Tract Infection, Acute Myocardial Infarction, Congestive Heart Failure, StrokeClinicalTrials.gov
InterventionsFlublok Quadrivalent, Standard Dose Inactivated Influenza Vaccine (SD-IIV)ClinicalTrials.gov
Lead sponsorKaiser PermanenteClinicalTrials.gov
Results first posted2025-04-08ClinicalTrials.gov
Results on ClinicalTrials.govhttps://clinicaltrials.gov/study/NCT03694392?tab=resultsClinicalTrials.gov

Source 4

FieldValueSource
Releasetrial-comparisons-2026-03-23-0.1.0ClinicalTrials.gov
Release manifest SHA-256f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57ClinicalTrials.gov
AACT copy2026-03-23ClinicalTrials.gov
Tables readoutcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquetClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.